
|Videos|January 19, 2023
Optimizing Patient Outcomes with JAK Inhibitors
Author(s)Brett King, MD, PhD, Alexandra K. Golant, MD
Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5






















